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INTRODUCTION
Patients	with	ovarian	cancer	have	a	high	risk	of	developing	
deep	venous	thrombosis	(DVT)	[1].	A	symptomatic	venous	
thromboembolism	has	been	reported	to	correlate	with	prog-
nosis	in	ovarian	cancer	[2].	Therefore,	accurate	diagnosis	of	
DVT	is	required	to	appropriately	treat	patients	with	this	dis-
ease.	D-dimer	(DD)	is	known	to	be	a	useful	molecular	marker	
of	blood	coagulation	and	fibrinolysis	[3-5].	DD	is	a	specific	
degradation	product	resulting	from	the	digestion	of	cross-
linked	fibrin	by	plasmin.	High	DD	levels	are	to	be	expected	
with	increased	fibrin	formation	and	an	efficient	fibrinolytic	
system.	The	presumption	is	that	DD	levels	will	be	elevated	in	
cases	of	ovarian	cancer;	however,	the	levels	of	DD	indicative	
of	DVT	remain	unclear.	Ultrasonography	using	vein	compres-
sion	and	color	Doppler	reveals	deep	venous	thrombi.	The	
present	study	sought	to	evaluate	the	usefulness	of	DD	levels	
and	subsequent	venous	ultrasonography	in	diagnosing	DVT	
prior	to	the	treatment	of	ovarian	cancer,	and	also	to	elucidate	
the	incidence	of	DVT	and	the	appropriate	cut-off	value	for	DD	
to	aid	in	the	diagnosis	of	DVT.
MATERIALS AND METHODS
The	subjects	were	87	patients	with	presumed	ovarian	can-
cer	who	were	seen	at	the	Gynecology	Department	of	the	
Shizuokas	Cancer	Center	Hospital	between	July	2007	and	
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Objective:	The	purpose	of	the	present	study	was	to	elucidate	the	incidence	of	deep	venous	thrombosis	(DVT)	before	treatment	
in	ovarian	cancer	and	the	appropriate	cut-off	value	of	D-dimer	(DD)	for	the	diagnosis	of	DVT.	
Methods: Between	July	2007	and	October	2008,	eighty	seven	patients	with	presumed	ovarian	cancer	(final	diagnosis:	ovarian	
cancer,	n=59;	borderline	malignancy,	n=28)	were	enrolled.	Measurement	of	DD	levels	and	subsequent	venous	ultrasonography	
were	performed	before	treatment.	
Results:	The	mean	DD	level	was	4.1	µg/mL.	Subsequent	venous	ultrasonography	revealed	DVT	in	14	of	87	(16.1%)	patients	
(ovarian	cancer,	12	cases;	borderline	malignancy,	2	cases).	None	were	found	to	have	developed	DVT	if	they	had	a	DD	level	of	
<1.5	µg/mL.	If	1.5	µg/mL	was	used	as	a	cut-off	value	for	DD	levels	to	diagnose	DVT,	sensitivity,	specificity,	positive	predictive	
value,	and	negative	predictive	value	were	100%,	61.6%,	33.3%,	and	100%.	There	was	noclinical	onset	of	postoperative	
pulmonary	thromboembolism.	
Conclusion: Our	data	suggest	that	presumed	ovarian	cancer	patients	with	at	least	more	than	1.5	µg/mL	should	be	examined	
using	venous	ultrasonogaphy	to	detect	DVT.
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October	2008.	The	data	were	obtained	retrospectively	from	
each	patient’s	medical	record.	Tumors	of	59	patients	were	his-
tologically	diagnosed	as	ovarian	cancer	after	surgery,	and	the	
remaining	28	patients	were	ovarian	borderline	malignancy.	
Peripheral	blood	samples	were	collected	from	all	patients	
and	the	DD	levels	were	measured	on	the	first	visits	to	our	
outpatient	clinic	2-4	weeks	before	initial	treatment	of	ovarian	
cancer.	At	the	same	time,	physical	examination	(calf	tender-
ness,	distension	of	collateral	veins,	edema,	swelling	of	the	calf	
or	the	whole	affected	limb)	were	performed.	The	plasma	DD	
level	was	measured	using	LPIA-ACE	DD	reagent	(Mitsubishi	
Chemical	Medicine	Co.,	Tokyo,	Japan)	and	JIF23	monoclonal	
antibody.	The	JIF23	monoclonal	antibody,	which	recognizes	
the	plasmin-digested	N-terminus	of	the	γ	chain	in	the	D	re-
gion	of	fibrin,	was	used	for	latex	agglutination.	
Venous	ultrasonography	was	performed	to	detect	DVT	in	all	
patients	using	a	LOGIQ	9	ultrasound	scanner	(GE	Healthcare,	
Willowick,	OH,	USA)	equipped	with	a	4-7	MHz	transducer.	Ve-
nous	lumina	were	observed	while	searching	for	thrombi	by	
manual	compression	with	a	transducer	and	color	Doppler	im-
aging.	Patients	with	DVT	detected	by	venous	ultrasonography	
underwent	enhanced	computed	tomography	of	the	lungs	to	
diagnose	pulmonary	thromboembolism	(PTE).	
We	performed	anticoagulant	therapy	using	unfractionated	
heparin	before	initial	treatment	and	after	surgery	for	all	pa-
tients	with	DVT.	An	inferior	vena	cava	filter	(IVC-F)	was	used	
immediately	before	surgery	to	prevent	lethal	PTE	in	patients	
with	a	deep	venous	thrombus	in	proximal	veins	(1	patient),	
such	as	the	iliac	and	femoral	veins,	or	a	floating	deep	venous	
thrombus	in	peripheral	veins	(4	patients).
For	patients	without	DVT,	intermittent	pneumatic	compres-
sion	was	used	during	and	after	surgery.	Low-molecular-weight	
heparin	was	administered	after	surgery	to	prevent	postopera-
tive	venous	thromboembolism	(VTE).	
The	protocol	for	this	research	project	was	approved	by	the	
Ethics	Committee	of	Shizuoka	Cancer	Center	Hospital	and	
conforms	to	the	Declaration	of	Helsinki.	All	patients	provided	
written	informed	consent.	Data	are	expressed	as	mean	values.	
The	differences	between	the	groups	were	tested	for	statistical	
significance	using	the	Mann-Whitney	U-test	and	the	χ
2	test.	A	
p-value	of	less	than	0.05	was	considered	significant.	All	statisti-
cal	analyses	were	performed	using	an	SPSS	ver.	11.0	(SPSS	Inc.,	
Chicago,	IL,	USA).
RESULTS
The	mean	age	of	all	patients	was	58.1	years	(range,	21	to	
85	years)	and	the	mean	BMI	was	21.9	(range,	16.6	to	33.7).	
The	mean	tumor	diameter	was	105.7	mm	(20	to	270	mm).	
The	mean	DD	level	was	4.1	µg/mL	(range,	0.2	to	91.8	µg/mL).	
Subsequent	venous	ultrasonography	revealed	DVT	in	14	of	87	
patients	(16.1%).	Patients	with	DVT	included	2	patients	with	
ovarian	borderline	malignancy.	
The	87	patients	were	divided	into	2	groups	depending	on	
whether	they	also	had	(14	patients)	or	did	not	have	(73	pa-
tients)	DVT;	the	results	of	a	comparison	of	the	2	groups	are	
shown	in	Table	1.	There	was	no	significant	difference	between	
the	groups	in	terms	of	age,	BMI,	and	tumor	size.	In	contrast	
to	a	mean	DD	level	of	2.2	µg/mL	in	the	patients	who	did	
not	have	DVT,	patients	who	also	had	DVT	had	a	significantly	
higher	mean	DD	level	of	13.2	µg/mL.	However,	differences	
between	the	2	groups	in	terms	of	histology,	stage	of	progres-
sion,	and	perioperative	volume	of	ascites	were	not	noted.	
Moreover,	mean	levels	of	DD	of	FIGO	stage	I/II	were	higher	
than	FIGO	stage	III/IV,	but	this	difference	was	not	statistically	
significant	(Table	2).	
Table 1.  Clinical characteristics of ovarian cancer patients
Clinical characteristics
DVT absent 
(n=73)
DVT present 
(n=14)
p-value
Age (yr) 57.6±14.7 60.0±10.9 0.436
BMI 21.2±3.1 22.3±2.9 0.552
Tumor diameter (mm) 107.6±60.9 96.8±65.6 0.539
D-dimer (µg/mL)  2.2±2.7  
(0.3-13.6)
13.2±22.9 
(1.3-91.8)
0.001
Histology   0.467
   Borderline malignancy 26 (35.6) 2 (14.3)
   Serous 16 (21.9) 6 (42.9)
   Endometrioid 13 (17.8) 2 (14.3)
   Clear cell 17 (23.3) 3 (21.4)
   Others 1 (1.4) 1 (7.1)
FIGO stage   0.314
   I/II 45 (61.6) 4 (7.1)
   III/IV 28 (38.4) 10 (92.9)
Ascites (mL) 0.548
   >2,000  31 (42.5) 7 (50.0)
   ≤2,000  42 (57.5) 7 (50.0)
Values are presented as number (%) or mean±SD.
DVT, deep venous thrombosis. 
Table 2. Mean difference within FIGO stage 
FIGO stage No. D-dimer (µg/mL)
I/II 37 2.2±2.3
III/IV 40    6.9±15.1Ryuji Kawaguchi, et al.
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In	87	patients,	the	site	where	DVT	was	located	was	in	the	
left	leg	in	3	patients,	in	the	right	leg	in	6,	and	in	both	legs	in	
5.	Thirteen	patients	had	DVT	in	the	lower	leg,	primarily	in	the	
veins	of	the	soleus	muscle,	and	only	1	patient	had	DVT	in	
the	femoral	vein.	PTE	was	not	noted	preoperatively	in	any	of	
the	patients.	Thirteen	patients	with	DVT	were	asymptomatic	
when	DVT	was	found.	However,	only	one	patient	with	DVT	in	
the	femoral	vein	experienced	calf	tenderness	and	swelling	of	
the	calf.	
The	relationship	between	DD	levels	and	the	incidence	of	
DVT	is	shown	in	Table	3.	Among	the	patients,	none	were	
found	to	have	developed	DVT	if	they	had	a	DD	level	of	<1.0	
µg/mL;	however,	DVT	was	noted	in	16.1%	of	patients	with	
1.0	µg/mL≤DD≤3.0	µg/mL,	in	21.1%	of	those	with	3.0	µg/
mL<DD≤10.0	µg/mL,	and	in	71.4%	of	those	with	a	DD	level	of	
>10.0	µg/mL.	DVT	was	found	in	all	of	the	ovarian	cancer	pa-
tients	with	a	DD	level	of	>10.0	µg/mL.
Shown	in	Table	4	are	the	sensitivity,	specificity,	positive	pre-
dictive	value	(PPV),	and	negative	predictive	value	(NPV)	of	DD	
levels	in	predicting	DVT	in	patients	with	presumed	ovarian	
cancer.	Raising	the	cut-off	value	for	DD	resulted	in	a	higher	
specificity	and	PPV	and	a	lower	sensitivity	and	NPV.	None	were	
found	to	have	developed	DVT	if	they	had	a	DD	level	of	<1.5	
µg/mL.	If	1.5	µg/mL	was	used	as	a	cut-off	value	for	DD	levels	
to	diagnose	DVT,	sensitivity,	specificity,	PPV,	and	NPV	were	
100%,	61.6%,	33.3%,	and	100%	(Table	3).	
A	temporary	IVC-F	was	inserted	preoperatively	in	5	patients.	
The	indications	for	filter	placement	were	as	follows:	1)	a	femo-
ral	deep	venous	thrombus	(1	patient)	and	2)	a	free-floating	
thrombus	(4	patients).	Of	these	5	patients,	one	developed	PTE	
postoperatively.	This	patient	had	a	DD	level	of	15.8	µg/mL	pre-
operatively;	venous	ultrasonography	of	the	lower	extremities	
revealed	a	DVT	in	the	right	femoral	vein.	For	this	reason,	the	
IVC-F	was	placed	preoperatively	and	the	patient	subsequently	
underwent	anticoagulant	therapy	with	heparin.	On	postop-
erative	day	8,	the	IVC-F	was	removed;	however,	on	day	9	the	
patient	developed	a	sub-massive	PTE.	After	the	onset,	uroki-
nase	was	administered	in	addition	to	heparin,	whereupon	the	
patient’s	symptoms	abated,	and	the	patient	was	discharged	
on	postoperative	day	24.	Apart	from	this	patient,	no	other	pa-
tient	developed	postoperative	PTE.
DISUCUSSION
Since	the	publication	of	the	Prevention	of	Venous	Thrombo-
embolism	Guidelines	of	the	American	College	of	Chest	Physi-
cians	(ACCP)	[6],	postoperative	prevention	of	PTE	has	become	
widely	prevalent.	However,	more	than	80%	of	PTE	occurs	
secondary	to	a	DVT	in	veins	in	the	leg	or	pelvis,	and	in	more	
than	40%	of	the	cases	of	DVT,	PTE	will	develop	if	the	DVT	is	left	
untreated	[7,8].	Important	questions	for	the	future	are	how	to	
screen	preoperatively	for	DVT	and,	if	DVT	is	found,	what	type	
of	PTE	prophylaxis	should	be	performed.
In	patients	with	ovarian	cancer,	a	massive	tumor	forms	in	
the	pelvis.	As	a	consequence,	venous	blood	flow	in	the	lower	
extremities	often	stagnates,	and	a	large	volume	of	ascites	fa-
cilitates	intravascular	hypovolemia	and	the	ready	formation	of	
thrombi	[9,10].	Moreover,	ovarian	cancer	involves	a	consider-
ably	larger	number	of	cancer	cells	than	other	types	of	cancer;	
consequently,	an	extremely	large	amount	of	tissue	factor	(TF),	
which	plays	a	role	in	thrombogenesis	[11,12],	is	released	by	
the	cancer	cells	[1].	Given	this	fact,	a	large	number	of	patients	
Table 3. Incidence of deep venous thrombosis for each level of D-dimer (DD)
Level of DD（µg/mL）
0≤DD<1.0 1.0≤DD≤3.0 3.0<DD≤10.0 10.0<DD
Total (n=87) 0/30 (0) 5/31 (16.1) 4/19 (21.1) 5/7 (71.4)
   Ovarian cancer (n=59) 0/14 (0) 3/22 (13.6) 4/18 (22.2) 5/5 (100)
   Borderline malignancy (n=28) 0/16 (0) 2/9 (22.20) 0/1 (0) 0/2 (0)
Values are presented as number (%).
Table 4. Sensitivity, specificity, PPV, and NPV of different cut-off 
D-dimer levels for diagnosis of DVT before treatment
Cut-off (µg/mL) Sensitivity Specificity PPV NPV
0.5 100 17.8  18.9 100
1.0 100 41.1 26.4 100
1.5 100 61.6 33.3 100
2.0 78.9 68.5 32.4 94.3
3.0 71.4 75.3 35.7 93.2
4.0 57.1 82.2 38.1 90.9
5.0 50.0 82.2 35.5 90.0
6.0 42.9 86.3 37.5 88.7
7.0 42.9 90.4 46.1 88.7
10.0 28.9 95.9 57.1 87.5
PPV, positive predictive value; NPV, negative predictive value; DVT, 
deep venous thrombosis. Cut-off value of D-dimer for prediction of DVT
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with	ovarian	cancer	are	presumed	to	have	already	developed	
VTE	prior	to	cancer	treatment	[1].	TF,	a	lipophilic	phospholi-
poprotein	transmembrane	receptor	with	potent	procoagu-
lant	activity,	is	expressed	in	ovarian	cancer.	This	expression	is	
significantly	correlated	with	VTE	development	in	clinical	situ-
ations.	Procoagulant	activity	with	DD	elevation	may	be	medi-
ated	by	TF	expression	in	ovarian	cancer	[13].
In	the	present	study,	we	measured	DD	and	performed	ve-
nous	ultrasonography	of	the	lower	extremities	in	all	patients	
with	presumed	ovarian	cancer.	DVT	was	noted	in	12	patients	
with	ovarian	cancer	(20.3%)	and	2	patients	with	borderline	
malignancy	(7.1%).	In	other	words,	our	results	revealed	that	
1	in	5	patients	with	ovarian	cancer	developed	DVT	preop-
eratively.	No	symptoms	of	DVT	were	noted	in	13	out	of	14	
patients	with	DVT.	Therefore,	physical	examination	in	patients	
suspected	of	DVT	is	of	limited	value	to	identify	patients	with	a	
low	or	high	probability	of	DVT.	
Typically,	postoperative	intermittent	pneumatic	compres-
sion,	as	is	used	to	prevent	the	onset	of	PTE,	is	contraindicated	
when	DVT	is	present.	A	failure	to	have	screened	for	DVT	in	the	
14	patients	with	ovarian	cancer	in	whom	DVT	was	noted	pre-
operatively	could	have	led	to	inappropriate	treatment	for	the	
prevention	of	PTE.	In	addition,	recent	research	has	indicated	
that	among	the	types	of	ovarian	cancer,	DVT	often	develops	
in	cases	of	clear	cell	adenocarcinoma	[13-15].	In	the	present	
study,	however,	we	found	no	such	high	incidence	of	DVT	in	
cases	of	clear	cell	adenocarcinoma.
In	diagnostic	imaging	used	to	detect	DVT,	contrast	venog-
raphy	is	the	gold	standard;	however,	its	invasiveness,	i.e.,	its	
use	of	a	contrast	material,	presents	a	problem.	Venous	ul-
trasonography	of	the	lower	extremities	is	a	simple	and	non-
invasive	examination	and	can	be	performed	repeatedly	at	the	
patient’s	bedside.	With	the	B-mode	compression	technique,	
the	presence	or	absence	of	a	thrombus	shadow	and	the	pres-
ence	or	absence	of	venous	collapse	due	to	the	compression	
of	veins	in	the	lower	extremities	are	crucial.	An	examination	is	
performed	while	repeatedly	compressing	the	veins	and	then	
releasing	that	pressure;	if	the	examination	still	fails	to	clearly	
indicate	whether	DVT	is	present,	color	Doppler	is	used	[16-18].	
Distal	muscles	are	compressed	while	viewing	color	Doppler	
images	to	ascertain	the	presence	or	absence	of	blood	flow	
around	the	thrombus.	Although	ultrasonography	of	veins	in	
the	lower	extremities	is	a	simple	procedure	that	can	be	quick-
ly	performed,	it	does	present	several	problems.	For	example,	
diagnosing	a	deep	venous	thrombus	in	veins	in	the	pelvis	is	
difficult,	and	the	ultrasonographer	must	be	experienced	in	or-
der	to	diagnose	a	deep	venous	thrombus	in	the	femoral	vein.	
Typically,	venous	ultrasonography	of	the	lower	extremities	to	
dia	 gnose	DVT	has	a	sensitivity	of	97%	and	a	specificity	of	94%	[19].
The	DD	levels	used	to	predict	DVT	generally	have	a	high	
sensitivity	and	NPV	of	80-100%,	but	a	low	specificity	and	PPV	
of	approximately	20-60%	[20,21].	In	other	words,	if	DD	is	at	its	
normal	level,	then	DVT	is	not	present.	However,	the	DD	level	
has	a	low	specificity	and	PPV;	therefore,	DVT	may	not	neces-
sarily	be	present	despite	a	high	DD	level.	In	addition,	a	report	
based	on	patients	in	whom	DVT	was	ruled	out	because	DD	
was	also	negative	indicated	that	such	patients	had	a	0.4%	
probability	of	developing	DVT7.	If	the	cut-off	value	for	pa-
tients	with	cancer	is	set	to	0.5	µg/mL,	then	their	positivity	for	
DD	will	typically	be	higher	than	that	of	patients	without	can-
cer	[22].	Thus,	caution	is	required	when	interpreting	DD	levels;	
definitive	diagnosis	of	DVT	requires	not	only	measurement	of	
a	certain	DD	level	but	also	some	form	of	diagnostic	imaging.	
From	the	perspective	of	cost-effectiveness,	an	imaging	study	
should	be	performed	when	DD	is	above	a	certain	level.	In	the	
present	study,	the	cut-off	value	for	DD	in	predicting	DVT	was	
determined	to	be	1.5	µg/mL.	A	suitable	cut-off	value	for	de-
tecting	DVT	in	patients	with	presumed	ovarian	cancer	appears	
to	be	1.5	µg/mL,	as	this	has	a	100%	sensitivity,	a	100%	NPV.	
However,	this	cut-off	value	had	only	a	61.6%	specificity	and	a	
33.3%	positive	predictive	value.	Therefore,	performing	venous	
ultrasonography	at	DD	levels	in	excess	of	1.5	µg/mL	might	im-
prove	the	detection	rate	of	DVT.	
In	conclusion,	this	study	demonstrates	that	DVT	occurs	be-
fore	treatment	of	ovarian	cancer	in	at	least	16.1%	of	patients.	
Venous	ultrasonography	should	be	performed	prior	to	treat-
ment	of	ovarian	cancer	in	patients	with	elevated	levels	of	DD	
(>1.5	µg/mL).	The	usefulness	of	preoperative	assessment	of	
DVT	needs	further	confirmation	in	randomized	controlled	tri-
als.	
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